De-Liang Ma
Papers
1
Total Citations
53
H-Index
1
About
De-Liang Ma is a leading clinical researcher in head and neck oncology, with a primary focus on human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. His most influential work centers on de-escalation strategies in adjuvant therapy, aiming to reduce treatment toxicity without compromising oncologic outcomes. Ma’s landmark contribution is the MC1675 Phase III trial, which directly compared de-escalated adjuvant radiation therapy (DART) against standard adjuvant treatment for HPV-positive oropharyngeal cancer. This study, cited over 50 times, has shaped ongoing debates about risk-adapted therapy and quality of life in cancer survivors. By challenging the necessity of aggressive radiation in low-risk populations, Ma’s research has influenced clinical guidelines and spurred further trials on treatment de-intensification. His work bridges the gap between precision oncology and patient-centered care, offering a paradigm shift in how we manage HPV-driven head and neck cancers. For students and researchers, Ma exemplifies how rigorous trial design can translate into meaningful changes in clinical practice, reducing long-term morbidity while maintaining high cure rates.
Research Focus
Key Achievements
Top Papers
- 1